These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 29189999)
1. NAFLD/NASH in patients with type 2 diabetes and related treatment options. Radaelli MG; Martucci F; Perra S; Accornero S; Castoldi G; Lattuada G; Manzoni G; Perseghin G J Endocrinol Invest; 2018 May; 41(5):509-521. PubMed ID: 29189999 [TBL] [Abstract][Full Text] [Related]
2. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [TBL] [Abstract][Full Text] [Related]
3. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280 [TBL] [Abstract][Full Text] [Related]
4. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. Della Pepa G; Vetrani C; Lombardi G; Bozzetto L; Annuzzi G; Rivellese AA Nutrients; 2017 Sep; 9(10):. PubMed ID: 28954437 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558 [TBL] [Abstract][Full Text] [Related]
6. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333 [TBL] [Abstract][Full Text] [Related]
7. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Perumpail RB; Wong RJ; Ahmed A; Harrison SA Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831 [TBL] [Abstract][Full Text] [Related]
8. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Lonardo A; Ballestri S; Targher G; Loria P Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):629-50. PubMed ID: 25327387 [TBL] [Abstract][Full Text] [Related]
9. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ; J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290 [TBL] [Abstract][Full Text] [Related]
10. Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne. Kosmidou M; Milionis H Minerva Endocrinol; 2017 Jun; 42(2):109-121. PubMed ID: 27990792 [TBL] [Abstract][Full Text] [Related]
11. The role of incretin hormones and glucagon in patients with liver disease. Junker AE Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease. Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423 [TBL] [Abstract][Full Text] [Related]
13. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Satapathy SK; Sanyal AJ Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640 [TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. Godinez-Leiva E; Bril F Curr Hypertens Rev; 2021; 17(2):94-111. PubMed ID: 33302841 [TBL] [Abstract][Full Text] [Related]
15. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986 [TBL] [Abstract][Full Text] [Related]
16. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. Stål P World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963 [TBL] [Abstract][Full Text] [Related]